80 related articles for article (PubMed ID: 21270615)
41. Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas.
Baykal C; Ayhan A; Al A; Yüce K; Ayhan A
Gynecol Oncol; 2003 Feb; 88(2):123-9. PubMed ID: 12586590
[TBL] [Abstract][Full Text] [Related]
42. Clinical and prognostic significance of human papillomavirus in a Chinese population of cervical cancers.
Lo KW; Cheung TH; Chung TK; Wang VW; Poon JS; Li JC; Lam P; Wong YF
Gynecol Obstet Invest; 2001; 51(3):202-7. PubMed ID: 11306910
[TBL] [Abstract][Full Text] [Related]
43. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor.
Wei LH; Kuo ML; Chen CA; Cheng WF; Cheng SP; Hsieh FJ; Hsieh CY
Gynecol Oncol; 2001 Jul; 82(1):49-56. PubMed ID: 11426961
[TBL] [Abstract][Full Text] [Related]
44. The prognostic role of human papillomavirus in patients with vaginal cancer.
Brunner AH; Grimm C; Polterauer S; Hefler L; Stani J; Heinze G; Horvat R
Int J Gynecol Cancer; 2011 Jul; 21(5):923-9. PubMed ID: 21666483
[TBL] [Abstract][Full Text] [Related]
45. No relationship is indicated between FHIT expression and clinicopathologic prognostic parameters in early stage cervical carcinoma.
Baykal C; Ayhan A; Al A; Yüce K; Ayhan A
Int J Gynecol Cancer; 2003; 13(2):192-6. PubMed ID: 12657123
[TBL] [Abstract][Full Text] [Related]
46. EGFR and phosphorylated EGFR in relation to HPV and clinical outcome in tonsillar cancer.
Romanitan M; Näsman A; Munck-Wikland E; Dalianis T; Ramqvist T
Anticancer Res; 2013 Apr; 33(4):1575-83. PubMed ID: 23564800
[TBL] [Abstract][Full Text] [Related]
47. High-risk human papillomavirus infection and E6 protein expression in lesions of the uterine cervix.
Pillai MR; Lakshmi S; Sreekala S; Devi TG; Jayaprakash PG; Rajalakshmi TN; Devi CG; Nair MK; Nair MB
Pathobiology; 1998; 66(5):240-6. PubMed ID: 9732239
[TBL] [Abstract][Full Text] [Related]
48. The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer.
Sznurkowski JJ; Żawrocki A; Biernat W
BMC Cancer; 2016 Jul; 16():465. PubMed ID: 27411473
[TBL] [Abstract][Full Text] [Related]
49. "Low-risk" and "high-risk" HPV-infection and K-ras gene point mutations in human cervical cancer: a study of 31 cases.
Stenzel A; Semczuk A; Rózyńskal K; Jakowicki J; Wojcierowski J
Pathol Res Pract; 2001; 197(9):597-603. PubMed ID: 11569923
[TBL] [Abstract][Full Text] [Related]
50. Lactate transporters and vascular factors in HPV-induced squamous cell carcinoma of the uterine cervix.
Pinheiro C; Garcia EA; Morais-Santos F; Scapulatempo-Neto C; Mafra A; Steenbergen RD; Boccardo E; Villa LL; Baltazar F; Longatto-Filho A
BMC Cancer; 2014 Oct; 14():751. PubMed ID: 25296855
[TBL] [Abstract][Full Text] [Related]
51. Expression and Significance of MTA2 and CPNE1 in Cervical Squamous Cell Carcinoma.
Wang L; Chen G; Zhou C; Wu C; Jiang J
Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):569-573. PubMed ID: 37399268
[TBL] [Abstract][Full Text] [Related]
52. Assessment of promising protein markers for vulva cancer.
Fons G; Burger MP; ten Kate FJ; van der Velden J
Int J Gynecol Cancer; 2009 May; 19(4):756-60. PubMed ID: 19509584
[TBL] [Abstract][Full Text] [Related]
53. Significance of erb-B2 immunoreactivity in cervical cancer.
Califano D; Losito S; Pisano C; Santelli G; Greggi S; Iodice F; DiVagno G; Silvestro G; Tambaro R; Formato R; Iaffaioli VR; Di Maio M; Pignata S
Front Biosci; 2006 Sep; 11():2071-6. PubMed ID: 16720293
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma.
Lerma E; Romero M; Gallardo A; Pons C; Muñoz J; Fuentes J; Lloveras B; Catasus L; Prat J
Virchows Arch; 2008 Jan; 452(1):65-74. PubMed ID: 18000680
[TBL] [Abstract][Full Text] [Related]
55. COX-1 and COX-2 expression in stage I and II invasive cervical carcinoma: relationship to disease relapse and long-term survival.
Athavale R; Clooney K; O'Hagan J; Shawki H; Clark AH; Green JA
Int J Gynecol Cancer; 2006; 16(3):1303-8. PubMed ID: 16803521
[TBL] [Abstract][Full Text] [Related]
56. Re: "P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma".
Van de Putte G; Vach W
Gynecol Oncol; 2005 Aug; 98(2):335-6. PubMed ID: 16039312
[No Abstract] [Full Text] [Related]
57. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma.
Kim YT; Park SW; Kim JW
Gynecol Oncol; 2002 Oct; 87(1):84-9. PubMed ID: 12468347
[TBL] [Abstract][Full Text] [Related]
58. The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer.
Kang MK; Park W; Choi YL; Cho EY; Ahn G; Nam H; Huh SJ; Ahn YC; Lim DH; Oh DR; Bae DS; Kim BG
J Korean Med Sci; 2009 Dec; 24(6):1170-6. PubMed ID: 19949677
[TBL] [Abstract][Full Text] [Related]
59. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer.
Scambia G; Ferrandina G; Distefano M; D'Agostino G; Benedetti-Panici P; Mancuso S
Cancer Lett; 1998 Jan; 123(2):135-9. PubMed ID: 9489479
[TBL] [Abstract][Full Text] [Related]
60. Correlation between tumor volume response to radiotherapy and expression of biological markers in patients with cervical squamous cell carcinoma.
Noh JM; Park W; Huh SJ; Cho EY; Choi YL; Lee JH; Bae DS
J Gynecol Oncol; 2009 Dec; 20(4):215-20. PubMed ID: 20041097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
